Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis

B. Bass, B. Weinshenker, G. P.A. Rice, J. H. Noseworthy, M. G.P. Cameron, W. Hader, S. Bouchard, G. C. Ebers

Research output: Contribution to journalArticlepeer-review

73 Scopus citations

Abstract

Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial. Each medication was introduced over a three week titration period and then maintained at the highest tolerated dose for five weeks. The two treatment phases were separated by a one week drug withdrawal and a two week washout period. Sixty-six patients entered the trial and forty-eight completed both treatment phases. At the end of the trial, neurologists and physiotherapists thought that baclofen was superior on the basis of perceived efficacy and tolerance (p≤0.05). Although the efficacy of tizanidine or baclofen was judged as good to excellent by 24 and 39% of patients respectively, this difference was not statistically significant. Muscle weakness was the most common adverse effect. This was significantly more troublesome in patients treated with baclofen. Somnolence and xerostomia were more common in patients treated with tizanidine. Both baclofen and tizanidine appear to be useful adjuncts in the treatment of spasticity in patients with multiple sclerosis. Preference of either drug is tempered principally by side-effects.

Original languageEnglish (US)
Pages (from-to)15-19
Number of pages5
JournalCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Volume15
Issue number1
DOIs
StatePublished - Feb 1988

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this